Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Heather A. Wakelee, Alexander Luft et al.|The Lancet|2021Cited by 1.5k
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Heather A. Wakelee, Enriqueta Felip, Nasser K. Altorki et al.|Journal of Clinical Oncology|2021Cited by 117
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, Nabil F. Saba et al.|JAMA Oncology|2018Cited by 111